Placental Alkaline Phosphatase (PLAP)
Immunology
Description
The main application of all tumour markers is monitoring for relapse or progression. Use as a diagnostic aid requires care and knowledge of the test limitations. Opportunistic screening is discouraged. Placental alkaline phosphatase (PLAP), in association with AFP and hCG, is of value in the diagnosis and monitoring of gonadal and extragonadal germ cell tumours [1,2]. Elevated levels of this marker are seen in 55% of seminoma and combined tumour and 60% of dysgerminoma. Levels are not usually elevated in teratomata. Elevated levels may also be seen in some epithelial carcinomas of the ovary, although PLAP does not contribute greatly to the management of this malignancy and the specificity is such that it offers no advantage over CA125 [1]. PLAP has a biological half-life of less than three days, therefore this marker is of value in the monitoring of post primary treatment response and will be of particular value in patients with Stage I disease being managed by a surveillance only regimen [1]. PLAP levels in the CSF can be considered as diagnostic for pineal germinoma [1,3].
Indications
Monitoring and diagnosis (with AFP and BHCG) of germ cell tumours.
Sample Type
2mL Serum (Gel 5mL Yellow tube ), or 1mL CSF. Store at +4C for up to 72hrs otherwise store frozen at -20C. Requests from outside Sheffield: Transport at ambient temperature via Royal Mail or Courier.
Reference Range
Serum: < 0.5 U/L (Non-smokers).
CSF: < 0.3 U/L.
Levels up to 1.5 U/L may be seen in moderate (one pack per day) cigarette smokers and somewhat higher levels in heavy smokers. Reference ranges established by in-house validation of the manufacturers information.
Turnaround Time
Within 5 days
Testing Frequency
Weekly
External Notes
Tumour Markers are not diagnostic and are of most use in monitoring response to treatment and early detection of relapse. Normal values do NOT exclude malignancy.
References
PRU handbook of Clinical Immunochemistry. 9th Edition. 2007. [Ref 1]Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005.18(Suppl 2):S61-79. Koshida K, et al. Significance of placental alkaline phosphatase (PLAP) in the monitoring of patients with seminoma. Br J Urol. 1996. 77(1):138-142. [Ref 2].=Shinoda J, et al. Placental alkaline phosphatase as a marker of primary intercranial germinoma. J Neurosurgery. 1988. 68(5):710-720. [Ref 3]
Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.
Your contact for this test
Clare Del-Duca BSc (Hons) Biomedical Science, MSc Pathological Science
Laboratory Manager - Immunology and Protein Reference Unit
You are enquiring about
Placental Alkaline Phosphatase (PLAP)